NO20071794L - Disubstituerte pyrazolobenzodiazepiner nyttige som inhibitorer for CDK2 og angiogenese, og for behandling av bryst, tarm, lunge og prostata cancer - Google Patents

Disubstituerte pyrazolobenzodiazepiner nyttige som inhibitorer for CDK2 og angiogenese, og for behandling av bryst, tarm, lunge og prostata cancer

Info

Publication number
NO20071794L
NO20071794L NO20071794A NO20071794A NO20071794L NO 20071794 L NO20071794 L NO 20071794L NO 20071794 A NO20071794 A NO 20071794A NO 20071794 A NO20071794 A NO 20071794A NO 20071794 L NO20071794 L NO 20071794L
Authority
NO
Norway
Prior art keywords
treatment
cdk2
breast
angiogenesis
lung
Prior art date
Application number
NO20071794A
Other languages
English (en)
Inventor
Peter Michael Wovkulich
Jin-Jun Liu
Kin-Chun Luk
Giacomo Pizzolato
Yi Ren
Kshitij Chhabilbhai Thakkar
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071794(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20071794L publication Critical patent/NO20071794L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer forbindelser med formelen hvor R1, R2, R3 og R4 er som definert i beskrivelsen. Oppfinnelsen tilveiebringer også fremgangsmåter for fremstilling av slike forbindelser og farmasøytiske preparater inneholdende dem. Oppfinnelsen tilveiebringer videre metoder for å hemme kinaser, spesielt CDK2, for å hemme angiogenese og for behandling av kreft, spesielt bryst-, kolon-, prostata- og lungekreft.
NO20071794A 2004-10-13 2007-04-03 Disubstituerte pyrazolobenzodiazepiner nyttige som inhibitorer for CDK2 og angiogenese, og for behandling av bryst, tarm, lunge og prostata cancer NO20071794L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61817404P 2004-10-13 2004-10-13
PCT/EP2005/010653 WO2006040036A1 (en) 2004-10-13 2005-10-04 Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer

Publications (1)

Publication Number Publication Date
NO20071794L true NO20071794L (no) 2007-07-10

Family

ID=35311946

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071794A NO20071794L (no) 2004-10-13 2007-04-03 Disubstituerte pyrazolobenzodiazepiner nyttige som inhibitorer for CDK2 og angiogenese, og for behandling av bryst, tarm, lunge og prostata cancer

Country Status (25)

Country Link
US (1) US7524840B2 (no)
EP (1) EP1802625B1 (no)
JP (1) JP2008515939A (no)
KR (1) KR100858262B1 (no)
CN (2) CN101899049A (no)
AR (1) AR051326A1 (no)
AT (1) ATE398619T1 (no)
AU (1) AU2005293818A1 (no)
BR (1) BRPI0518152A (no)
CA (1) CA2582985A1 (no)
DE (1) DE602005007623D1 (no)
DK (1) DK1802625T3 (no)
ES (1) ES2308551T3 (no)
HR (1) HRP20080429T3 (no)
IL (1) IL182423A0 (no)
MX (1) MX2007004464A (no)
NO (1) NO20071794L (no)
NZ (1) NZ554353A (no)
PL (1) PL1802625T3 (no)
PT (1) PT1802625E (no)
RU (1) RU2394826C2 (no)
SI (1) SI1802625T1 (no)
TW (1) TWI309652B (no)
WO (1) WO2006040036A1 (no)
ZA (1) ZA200702973B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
CA2624025A1 (en) * 2005-10-14 2007-04-19 F. Hoffmann-La Roche Ag Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
MY156727A (en) * 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP2011201794A (ja) * 2010-03-24 2011-10-13 Fujifilm Corp ５−アミノピラゾール誘導体及びその塩の製造方法
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
KR102703498B1 (ko) * 2015-09-23 2024-09-04 얀센 파마슈티카 엔브이 신규 화합물
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
CN106928040A (zh) * 2015-12-31 2017-07-07 上海医药工业研究院 Sglt2抑制剂中间体的制备方法
PL3551631T3 (pl) * 2016-12-12 2025-03-24 Kinoxis Therapeutics Pty Ltd Agoniści receptora oksytocyny nie będący peptydem
AU2017376353B2 (en) 2016-12-13 2020-02-06 Transthera Sciences (Nanjing), Inc. Multi-kinase inhibitor compound, and crystal form and use thereof
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
CN120051473A (zh) 2022-08-17 2025-05-27 韩国化学研究院 抑制或降解cdk2和/或cdk9的化合物及其医学用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681341A (en) 1970-12-23 1972-08-01 Hoffmann La Roche Process for preparing 1-lower alkyl-1,4-benzodiazepin-2-ones
ZA889116B (en) * 1987-12-18 1989-08-30 Hoffmann La Roche Tricyclic compounds
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
CN100577651C (zh) * 2000-12-01 2010-01-06 味之素株式会社 内酰胺化合物及其药物用途

Also Published As

Publication number Publication date
PT1802625E (pt) 2008-08-06
TW200628469A (en) 2006-08-16
JP2008515939A (ja) 2008-05-15
BRPI0518152A (pt) 2008-11-04
HK1108284A1 (en) 2008-05-02
IL182423A0 (en) 2007-07-24
CN101899049A (zh) 2010-12-01
SI1802625T1 (sl) 2008-10-31
CN101039946A (zh) 2007-09-19
DK1802625T3 (da) 2008-09-01
ATE398619T1 (de) 2008-07-15
ES2308551T3 (es) 2008-12-01
US7524840B2 (en) 2009-04-28
EP1802625A1 (en) 2007-07-04
HRP20080429T3 (en) 2008-09-30
AU2005293818A1 (en) 2006-04-20
DE602005007623D1 (de) 2008-07-31
KR100858262B1 (ko) 2008-09-11
EP1802625B1 (en) 2008-06-18
CN101039946B (zh) 2010-12-08
US20060079511A1 (en) 2006-04-13
PL1802625T3 (pl) 2008-12-31
RU2007117770A (ru) 2008-11-20
AR051326A1 (es) 2007-01-03
WO2006040036A1 (en) 2006-04-20
TWI309652B (en) 2009-05-11
CA2582985A1 (en) 2006-04-20
ZA200702973B (en) 2009-09-30
RU2394826C2 (ru) 2010-07-20
NZ554353A (en) 2010-01-29
KR20070054243A (ko) 2007-05-28
MX2007004464A (es) 2007-05-07

Similar Documents

Publication Publication Date Title
TW200628469A (en) Disubstituted pyrazolobenzodiazepines
BRPI0511975A (pt) pirazolopirimidinas
IL260127B (en) mek inhibitors and methods of using them
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
NO20081952L (no) Substituerte pyrazolforbindelser
GEP20125368B (en) Kinase inhibitors
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
MXPA05007352A (es) Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion.
PL1853602T3 (pl) Związki chemiczne
PL1853588T3 (pl) Związki chemiczne
TNSN08020A1 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
NO20044526L (no) Hemisterlinderivater og anvendelser derav
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
MXPA05006507A (es) Inhibidores de ccxckr2 expresado en tumor humano.
TW200716545A (en) Indole derivatives having anti-tumor activity
WO2005103034A8 (en) Novel piperidine substituted diaminothiazoles
UA96742C2 (en) Mek inhibitors and use thereof
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application